logo
    • English
      • 简体中文
      • 繁體中文
  • Home
  • Articles
    • Insights
    • Client Press Releases
    • Client Coverage
  • Interviews
    • CEO Interview
    • PDAC Interview
  • Clients
    • Featured Companies
    • In-depth Analysis
  • Markets
    • Stock Tracker
    • Markets at a glance
    • Investing 101
      • Investing in Mining 101
        • Gold and Precious Metals
        • Electric and Battery Metals
        • Base Metals
        • Other Mining Subsectors
  • METALS 100
  • GCFF Event
    • Next Event
    • Past Events
  • Home
  • Biotechnology
Filter

Biotechnology

Categories

Sectors

Locations

Exchange

Shenzhen Hepalink Invests $69 Million in Canada’s Resverlogix

Oct 16, 2017

Life Science

Naturally Splendid Enterprises Ltd TSXV:NSP Biotechnology, Nutraceutical, Consumer Products and Services, 生物科技,营养品,消费品,

Naturally Splendid NATERA(tm) CBD Products Granted Approval in Japanese Market with First Step Japan

Oct 16, 2017

Life Science

Naturally Splendid Enterprises Ltd TSXV:NSP Biotechnology, Nutraceutical, Consumer Products and Services, 生物科技,营养品,消费品,

Alumina Partners commits up to $6 mln to Naturally Splendid and Closes First Tranche Investment. Naturally Splendid also Extends Closing of Prosnack Acquisition.

Oct 16, 2017

Life Science

Resverlogix Corp TSX:RVX Pharmaceutical, Biotechnology, 医药,生物科技

Resverlogix Announces $87 Million Private Placement with Shenzhen Hepalink

Oct 13, 2017

Life Science

Resverlogix Corp TSX:RVX Pharmaceutical, Biotechnology, 医药,生物科技

IIROC Trading Halt – RVX

Oct 13, 2017

Life Science

Gentris and Shanghai Institute Sign MOU for Biomarker Collaboration

Oct 10, 2017

Life Science

DelMar Pharmaceuticals Inc NASDAQ:DMPI

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

Oct 3, 2017

Life Science

Redhill Biopharma Ltd NASDAQ:RDHL Pharmaceutical, Biotechnology,医药,生物科技

RedHill Biopharma Announces Positive Top-Line Results from Phase II Study of BEKINDA® in Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D)

Oct 3, 2017

Life Science

Redhill Biopharma Ltd NASDAQ:RDHL Pharmaceutical, Biotechnology,医药,生物科技

RedHill Biopharma Accelerates RHB-104 Phase III Study in Crohn’s Disease with Top-Line Results Expected Mid-2018

Oct 2, 2017

Life Science

Novo Nordisk Approved to Launch New Diabetes Treatment in China

Sep 29, 2017

Life Science

DelMar Pharmaceuticals Inc NASDAQ:DMPI

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

Sep 28, 2017

Life Science

China’s MeituanDianping Said To Raise $3 Billion From Tencent, IDG Capital

Sep 28, 2017

Technology

Simcere to Market Four Amgen Biosimilars in China

Sep 27, 2017

Life Science

DelMar Pharmaceuticals Inc NASDAQ:DMPI

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

Sep 27, 2017

Life Science

DelMar Pharmaceuticals Inc NASDAQ:DMPI

CEO Jeffery Bacha Discusses DelMar’s VOL-083 Clinical Trials and the Major Milestones Ahead

Sep 26, 2017

Life Science

Replicel Life Sciences Inc TSXV:RP Biotechnology, Medical Device, Genomics, 生物科技,医疗设备,基因组学

RepliCel Retains Hybrid Financial for Investor Relations

Sep 25, 2017

Life Science

VolitionRx Announces the Initial Sale of its New Nu.Q(TM) Research Kits

Sep 22, 2017

Life Science

DelMar Pharmaceuticals Inc NASDAQ:DMPI

DelMar Pharmaceuticals Announces Closing Of $10 Million Registered Direct Offering Priced At-The-Market

Sep 22, 2017

Life Science

  • ‹‹ Previous
  • 136
  • 137
  • 138
  • 139
  • 140
  • 141
  • 142
  • 143
  • 144
  • Next ››

We connect Investors to Opportunities.

Financial Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.

 
QuoteMedia logo

Head Office

  • 2209 – 1111 Alberni Street
    Vancouver, BC Canada V6E 4V2
  • Phone: (604) 488-8878
  • Fax: (604) 488-0868
  • Toll Free: 1 (866) 833-5517
  • Email: [email protected]

Shanghai Office

  • 06 - 607, 6/f. No.800 Shangcheng
    Road Pudong New District Shanghai,
    China
  • Phone: 021-68883919
  • Fax: 021-68882879
  • Email: [email protected]

Important Links

  • Privacy Policy
  • Terms of Use
  • Content Partner
  • NAI500 Investor Relations Services
  • About Us
  • Contact Us

© 2026 NAI Interactive Ltd. All Rights Reserved

gcff

logo

Website Design Vancouver by Nirvana Canada